BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...
The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the ...
Sebastien Beauzile, 21, became the first person in New York state to be made symptom-free of sickle cell disease after ...
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case had not previously been seen with the therapy, ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
Scientists at the Allen Institute have made a major breakthrough in research for people living with Dravet Syndrome, which is ...
By replacing the defective gene associated with Dravet syndrome in mice, scientists successfully alleviated symptoms without side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback